Cns Pharmaceuticals Inc (CNSP)

$5.22 +0.11 (2.13%)
Market Cap 7.47M
Revenue (ttm) 0.00
Net Income (ttm) -15.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,300
Avg Vol 7,244
Day's Range N/A - N/A
Shares Out 1.46M
Stochastic %K 6%
Beta 3.06
Analysts Strong Sell
Price Target $10.00

Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 946 9185
Address:
2100 West Loop South, Suite 900, Houston, United States
NetworkNewsWire
NetworkNewsWire Sep. 8 at 8:00 PM
Laser Therapy Shows Promise in Treating Brain Cancer $CNSP https://ibn.fm/Arlsc #tinygems #stocks
0 · Reply
NetworkNewsWire
NetworkNewsWire Sep. 4 at 5:59 PM
Timing of Brain Metastasis Predicts Survival of Colorectal Cancer Patients $CNSP #BioMed #Brain #Cancer https://ibn.fm/nCBEp
0 · Reply
VirtualInvestor
VirtualInvestor Sep. 1 at 3:40 PM
$CNSP Chief Business Officer, Dylan Wenke, joins Virtual Investor’s “What This Means” series to discuss the Company’s business development strategy as it builds an oncology or neurology pipeline with best-in-class potential. https://vimeo.com/1222840808/9bb3667cd1
0 · Reply
Cns_pharma
Cns_pharma Sep. 1 at 3:34 PM
$CNSP Details Business Development Strategy Driving Its Next Phase of Growth Chief Business Officer, Dylan Wenke, Participates in Virtual Investor “What This Means” Segment Access the segment here: https://virtualinvestorco.com/cnsp/ Press Release: https://cnspharma.com/cns-pharmaceuticals-details-business-development-strategy-driving-its-next-phase-of-growth/
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 27 at 5:10 PM
Covid-19 Vaccine Could Extend Survival of Brain Cancer Patients $CNSP #BioMed #Covid #Cancer https://ibn.fm/ACwVX
0 · Reply
VirtualInvestor
VirtualInvestor Aug. 27 at 2:21 PM
$CNSP Participates in the Virtual Investor "Why Now" On-Demand Conference Hope starts with pursuing what's possible. https://vimeo.com/1221551759/6f89b281ba?fl=ml&fe=ec
0 · Reply
Cns_pharma
Cns_pharma Aug. 27 at 2:13 PM
$CNSP Participates in the Virtual Investor "Why Now" On-Demand Conference Access the webcast here: https://virtualinvestorco.com/why-now/ Press Release: https://cnspharma.com/cns-pharmaceuticals-participates-in-the-virtual-investor-why-now-on-demand-conference/
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 24 at 7:54 PM
New T Cell Therapy Could Transform Glioblastoma Care $CNSP https://ibn.fm/02EqR #tinygems #stocks
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 18 at 7:50 PM
Researchers Identify a Protein That Could Be Targeted in Glioblastoma Therapy $CNSP #BioMed #Protein #Glioblastoma https://ibn.fm/17Ztq
0 · Reply
HappyStrider
HappyStrider Aug. 1 at 5:32 PM
W/L Monday: $RUBI main watch. $FCUV $APMD $SCYX $CNSP Going to be another hot week, good luck bulls.
1 · Reply
Latest News on CNSP
CNS Pharmaceuticals details business development strategy

2026-09-01T13:20:32.000Z - 20 days ago

CNS Pharmaceuticals details business development strategy

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

Sep 1, 2026, 9:01 AM EDT - 20 days ago

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

Aug 27, 2026, 9:01 AM EDT - 25 days ago

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

CNS Pharmaceuticals Proxy statement: Proxy filing

Aug 25, 2026, 8:00 AM EDT - 27 days ago

CNS Pharmaceuticals Proxy statement: Proxy filing

CNS Pharmaceuticals Proxy statement: Proxy filing

Aug 21, 2026, 8:00 AM EDT - 4 weeks ago

CNS Pharmaceuticals Proxy statement: Proxy filing

CNS Pharmaceuticals Slides: Investor presentation

Aug 17, 2026, 8:00 AM EDT - 5 weeks ago

CNS Pharmaceuticals Slides: Investor presentation

CNS Pharmaceuticals reports Q2 EPS (37c) vs. ($6.42) last year

2026-08-17T09:41:45.000Z - 5 weeks ago

CNS Pharmaceuticals reports Q2 EPS (37c) vs. ($6.42) last year

CNS Pharmaceuticals ‘actively evaluating’ business devlopment opportunities

2026-08-17T09:40:51.000Z - 5 weeks ago

CNS Pharmaceuticals ‘actively evaluating’ business devlopment opportunities

CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months

2026-08-17T09:40:41.000Z - 5 weeks ago

CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Aug 12, 2026, 8:00 AM EDT - 5 weeks ago

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

CNS Pharmaceuticals Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 5 weeks ago

CNS Pharmaceuticals Quarterly report: Q2 2026

CNS Pharmaceuticals Earnings release: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 5 weeks ago

CNS Pharmaceuticals Earnings release: Q2 2026

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

Jun 8, 2026, 9:15 AM EDT - 3 months ago

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

May 20, 2026, 9:02 AM EDT - 4 months ago

CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders

2026-05-19T21:01:10.000Z - 4 months ago

CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders

CNS Pharmaceuticals Registration statement: Registration filing

May 19, 2026, 8:00 AM EDT - 4 months ago

CNS Pharmaceuticals Registration statement: Registration filing

CNS Pharmaceuticals reports Q1 EPS ($7.30) vs. ($18.93) last year

2026-05-14T16:25:17.000Z - 4 months ago

CNS Pharmaceuticals reports Q1 EPS ($7.30) vs. ($18.93) last year

CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months

2026-05-14T16:22:47.000Z - 4 months ago

CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

May 14, 2026, 8:00 AM EDT - 4 months ago

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

CNS Pharmaceuticals Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

CNS Pharmaceuticals Quarterly report: Q1 2026

CNS Pharmaceuticals Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

CNS Pharmaceuticals Earnings release: Q1 2026

3 Penny Stocks to Watch Now, 5/5/26

2026-05-05T16:22:32.000Z - 4 months ago

3 Penny Stocks to Watch Now, 5/5/26

ELPW PN

Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?

2026-05-04T13:58:45.000Z - 4 months ago

Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?

CNS Pharmaceuticals prices 650,000 shares at $2.30 in private placement

2026-05-04T11:19:29.000Z - 4 months ago

CNS Pharmaceuticals prices 650,000 shares at $2.30 in private placement

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

May 4, 2026, 7:00 AM EDT - 4 months ago

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

CNS Pharmaceuticals Slides: Investor presentation

Apr 22, 2026, 7:00 AM EDT - 5 months ago

CNS Pharmaceuticals Slides: Investor presentation

CNS Pharmaceuticals Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 5 months ago

CNS Pharmaceuticals Annual report: Q4 2025

CNS Pharmaceuticals launches new corporate growth strategy

2026-03-11T12:52:04.000Z - 6 months ago

CNS Pharmaceuticals launches new corporate growth strategy

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

Mar 11, 2026, 8:35 AM EDT - 6 months ago

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

CNS Pharmaceuticals appoints Lynne Kelley as CMO

2026-03-02T13:42:54.000Z - 6 months ago

CNS Pharmaceuticals appoints Lynne Kelley as CMO

CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team

Mar 2, 2026, 8:25 AM EST - 6 months ago

CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team

CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO

2026-02-17T13:45:41.000Z - 7 months ago

CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation

Feb 17, 2026, 8:25 AM EST - 7 months ago

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation

CNS Pharmaceuticals says priority ‘is to transform’ how company operates

2026-01-27T14:15:45.000Z - 7 months ago

CNS Pharmaceuticals says priority ‘is to transform’ how company operates

CNS Pharmaceuticals Issues Letter to Shareholders

Jan 27, 2026, 9:00 AM EST - 7 months ago

CNS Pharmaceuticals Issues Letter to Shareholders

CNS Pharmaceuticals Inc trading resumes

2026-01-15T14:45:16.000Z - 8 months ago

CNS Pharmaceuticals Inc trading resumes

CNS Pharmaceuticals Inc trading halted, volatility trading pause

2026-01-15T14:35:44.000Z - 8 months ago

CNS Pharmaceuticals Inc trading halted, volatility trading pause

CNS Pharmaceuticals CEO John Climaco steps down, Rami Levin succeeds

2025-12-17T12:15:58.000Z - 9 months ago

CNS Pharmaceuticals CEO John Climaco steps down, Rami Levin succeeds

CNS Pharmaceuticals Announces CEO Transition

Dec 17, 2025, 7:00 AM EST - 9 months ago

CNS Pharmaceuticals Announces CEO Transition

CNS Pharmaceuticals reports Q3 EPS ($5.76) vs. ($153.20) last year

2025-11-17T14:01:48.000Z - 10 months ago

CNS Pharmaceuticals reports Q3 EPS ($5.76) vs. ($153.20) last year

CNS Pharmaceuticals sees cash runway into 2H26

2025-11-17T14:01:42.000Z - 10 months ago

CNS Pharmaceuticals sees cash runway into 2H26

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 17, 2025, 8:35 AM EST - 10 months ago

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 10 months ago

CNS Pharmaceuticals Quarterly report: Q3 2025

CNS Pharmaceuticals Proxy statement: Proxy Filing

Nov 12, 2025, 7:00 AM EST - 10 months ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

Nov 10, 2025, 8:45 AM EST - 10 months ago

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

CNS Pharmaceuticals Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 11 months ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Proxy statement: Proxy Filing

Oct 10, 2025, 8:00 AM EDT - 11 months ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 15, 2025, 8:05 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

CNS Pharmaceuticals Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Earnings release: Q2 2025

CNS Pharmaceuticals Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Quarterly report: Q2 2025

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

CNS Pharmaceuticals Announces Reverse Stock Split

Jul 18, 2025, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

Jul 9, 2025, 9:32 AM EDT - 1 year ago

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Jun 24, 2025, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

Jun 5, 2025, 8:05 AM EDT - 1 year ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 16, 2025, 8:05 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

CNS Pharmaceuticals Quarterly report: Q1 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025, 9:35 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

May 13, 2025, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

CNS Pharmaceuticals Registration statement: Registration Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Registration statement: Registration Filing

CNS Pharmaceuticals Registration statement: Registration Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Registration statement: Registration Filing

CNS Pharmaceuticals Earnings release: Q4 2024

Apr 1, 2025, 4:00 PM EDT - 1 year ago

CNS Pharmaceuticals Earnings release: Q4 2024

CNS Pharmaceuticals Annual report: Q4 2024

Apr 1, 2025, 4:00 PM EDT - 1 year ago

CNS Pharmaceuticals Annual report: Q4 2024

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Apr 1, 2025, 8:05 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Mar 25, 2025, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 26, 2025, 9:05 AM EST - 1 year ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 20, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 18, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Feb 10, 2025, 8:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

CNS Pharmaceuticals Transcript: Investor Update

Dec 11, 2024, 11:30 AM EST - 1 year ago

CNS Pharmaceuticals Transcript: Investor Update

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Dec 5, 2024, 9:10 AM EST - 1 year ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 25, 2024, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 18, 2024, 8:55 AM EST - 1 year ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 9:10 AM EST - 1 year ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Proxy statement: Proxy Filing

Nov 15, 2024, 7:00 AM EST - 1 year ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Quarterly report: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

CNS Pharmaceuticals Quarterly report: Q3 2024

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 4, 2024, 9:15 AM EST - 1 year ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Nov 1, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals Proxy statement: Proxy Filing

Oct 28, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 23, 2024, 2:50 PM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 16, 2024, 4:00 PM EDT - 1 year ago

CNS Pharmaceuticals Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

CNS Pharmaceuticals Proxy statement: Proxy Filing

Oct 15, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Proxy statement: Proxy Filing

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 10, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Oct 8, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 12, 2024, 9:00 AM EDT - 2 years ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 2 years ago

CNS Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:05 AM EDT - 2 years ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Sep 3, 2024, 8:00 AM EDT - 2 years ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 27, 2024, 9:10 AM EDT - 2 years ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals Transcript: Virtual Investor CEO Connect

Aug 26, 2024, 12:00 PM EDT - 2 years ago

CNS Pharmaceuticals Transcript: Virtual Investor CEO Connect

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 22, 2024, 9:15 AM EDT - 2 years ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 2 years ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNS Pharmaceuticals Quarterly report: Q2 2024

Aug 13, 2024, 6:00 PM EDT - 2 years ago

CNS Pharmaceuticals Quarterly report: Q2 2024

CNS Pharmaceuticals Transcript: Investor Update

Jul 30, 2024, 8:30 AM EDT - 2 years ago

CNS Pharmaceuticals Transcript: Investor Update

CNS Pharmaceuticals Press release: Investor Update

Jul 30, 2024, 8:30 AM EDT - 2 years ago

CNS Pharmaceuticals Press release: Investor Update

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 30, 2024, 7:00 AM EDT - 2 years ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 25, 2024, 9:05 AM EDT - 2 years ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

NetworkNewsWire
NetworkNewsWire Sep. 8 at 8:00 PM
Laser Therapy Shows Promise in Treating Brain Cancer $CNSP https://ibn.fm/Arlsc #tinygems #stocks
0 · Reply
NetworkNewsWire
NetworkNewsWire Sep. 4 at 5:59 PM
Timing of Brain Metastasis Predicts Survival of Colorectal Cancer Patients $CNSP #BioMed #Brain #Cancer https://ibn.fm/nCBEp
0 · Reply
VirtualInvestor
VirtualInvestor Sep. 1 at 3:40 PM
$CNSP Chief Business Officer, Dylan Wenke, joins Virtual Investor’s “What This Means” series to discuss the Company’s business development strategy as it builds an oncology or neurology pipeline with best-in-class potential. https://vimeo.com/1222840808/9bb3667cd1
0 · Reply
Cns_pharma
Cns_pharma Sep. 1 at 3:34 PM
$CNSP Details Business Development Strategy Driving Its Next Phase of Growth Chief Business Officer, Dylan Wenke, Participates in Virtual Investor “What This Means” Segment Access the segment here: https://virtualinvestorco.com/cnsp/ Press Release: https://cnspharma.com/cns-pharmaceuticals-details-business-development-strategy-driving-its-next-phase-of-growth/
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 27 at 5:10 PM
Covid-19 Vaccine Could Extend Survival of Brain Cancer Patients $CNSP #BioMed #Covid #Cancer https://ibn.fm/ACwVX
0 · Reply
VirtualInvestor
VirtualInvestor Aug. 27 at 2:21 PM
$CNSP Participates in the Virtual Investor "Why Now" On-Demand Conference Hope starts with pursuing what's possible. https://vimeo.com/1221551759/6f89b281ba?fl=ml&fe=ec
0 · Reply
Cns_pharma
Cns_pharma Aug. 27 at 2:13 PM
$CNSP Participates in the Virtual Investor "Why Now" On-Demand Conference Access the webcast here: https://virtualinvestorco.com/why-now/ Press Release: https://cnspharma.com/cns-pharmaceuticals-participates-in-the-virtual-investor-why-now-on-demand-conference/
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 24 at 7:54 PM
New T Cell Therapy Could Transform Glioblastoma Care $CNSP https://ibn.fm/02EqR #tinygems #stocks
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 18 at 7:50 PM
Researchers Identify a Protein That Could Be Targeted in Glioblastoma Therapy $CNSP #BioMed #Protein #Glioblastoma https://ibn.fm/17Ztq
0 · Reply
HappyStrider
HappyStrider Aug. 1 at 5:32 PM
W/L Monday: $RUBI main watch. $FCUV $APMD $SCYX $CNSP Going to be another hot week, good luck bulls.
1 · Reply
AC_TRADER
AC_TRADER Jul. 31 at 8:52 PM
$CNSP Levels made with @TrendSpider https://share.trendspider.com/chart/CNSP/75949f4i3w
0 · Reply
NetworkNewsWire
NetworkNewsWire Jul. 30 at 6:42 PM
Novel Vitamin B12 Treatment Offers Hope in Brain Cancer Treatment $CNSP https://ibn.fm/c0AUc #biomed #stocks
0 · Reply
NetworkNewsWire
NetworkNewsWire Jul. 27 at 6:54 PM
Experimental Immunotherapy Offers Hope Against Deadly Pediatric Brain Cancer $CNSP https://ibn.fm/IunaT #tinygems #stocks
0 · Reply
IronRod2
IronRod2 Jul. 24 at 4:49 PM
$CNSP $HIMS $FRMI $ZVRA $SLS CNSP BUY THE DIP. CNS Pharmaceuticals Breaking out imminent anytime now. Great Set up for explosive rally. Going all in for 10,000% gains. 🚀🚀CNSP🚀🚀🚀
1 · Reply
IronRod2
IronRod2 Jul. 24 at 6:06 AM
$CNSP Stellar
0 · Reply
jake0T
jake0T Jul. 24 at 5:55 AM
$CNSP $TNXP $ENSC $ISRG $HUMA Bullish Pendant Pattern. CNS-Pharmaceuticals CNSP is rebounding. 9700% next week Monday open. So this week Get on the CNS Pharmaceuticals CNSP moon rocket. FAST TRACK DESIGNATION + ORPHAN DRUG DESIGNATION + INTELLECTUAL PROPERTY COMMERCIALIZATION RIGHTS in E.U. & U.S.
0 · Reply
jake0T
jake0T Jul. 24 at 5:55 AM
$CNSP $CDT $EDBL $DHR $TMO Bull Flag Price action. CNS-Pharmaceuticals CNSP is rebounding. Now get on the CNS Pharmaceuticals CNSP moon rocket 9700% on Monday open. FAST TRACK DESIGNATION + ORPHAN DRUG DESIGNATION + INTELLECTUAL PROPERTY COMMERCIALIZATION RIGHTS in E.U. & U.S.
0 · Reply
NetworkNewsWire
NetworkNewsWire Jul. 21 at 2:38 PM
Study Finds No Evidence That Mobile Phones Can Cause Brain Cancer $CNSP https://ibn.fm/wL5MZ #biomed #stocks
0 · Reply
IronRod2
IronRod2 Jul. 20 at 7:31 PM
$CNSP $ACHR $IREN $ PSKY $NUAI $WBD $CIFR $ONDS $ PATH $TSSI $QXO $CNSP CNS Pharmaceuticals is rebounding. Get on the CNS moon rocket.
0 · Reply
ClarityOfPurpose2
ClarityOfPurpose2 Jul. 20 at 7:08 PM
$CNSP The best things that they do are to figure out ways to stay in business, draw their salaries, and stay on Nasdaq. Especially regarding the continued Nasdaq listing.
1 · Reply